Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 vs TB-500 — Peptide Comparison

BPC-157 vs TB-500 — Peptide Comparison BPC-157 vs TB-500 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range BPC-157 250–500 mcg TB-500 2–5 mg Frequency Once daily Twice week

This comparison does not assign a generated winner or score.

BPC-157 vs TB-500 — Peptide Comparison BPC-157 vs TB-500 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range BPC-157 250–500 mcg TB-500 2–5 mg Frequency Once daily Twice weekly Administration Subcutaneous injection Cycle Length 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Strong preclinical (extensive animal studies) Moderate human trials (Phase 1-2) Efficacy Primary Benefit Secondary Benefit Additional Benefit Healing Speed Tissue Repair Anti-Scarring Technical Data Molecular Formula C62H98N16O22 Molecular Weight 1419.53 g/mol Half-Life 4-6 hours Bioavailability ~100% (subcutaneous) CAS Number 137525-51-0 C38H68N10O14 889.01 g/mol 2-3 days (systemic) High via subcutaneous injection (~100%) 885340-08-9 Protocols starting 250 mcg 1-2 weeks A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2]. standard 250-500 mcg Twice daily Commonly used range for tissue and tendon recovery in research practice [1][3]. advanced 500 mcg 6-8 weeks Upper end used in practice for more demanding acute injuries [1][3]. 2-2.5 mg Loading phase, 4-6 weeks Research peptide with no human trials of the fragment; loading doses used in practice [6]. Once weekly Maintenance after loading Maintenance dose used in practice following the loading phase [6]. Applications Tendon and ligament injuries Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair Gut healing IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue Muscle injuries Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression Joint problems Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties Post-surgical recovery Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms Athletes Recovering from Muscle Injuries If you've pulled a hamstring, strained your back, or torn a muscle, TB-500 helps accelerate the healing process by promoting cell migration to the injury site and supporting new blood vessel growth. It's especially useful for injuries that just won't seem to fully heal. Tendon and Ligament Problems Tendons and ligaments are notoriously slow healers because they have poor blood supply. TB-500 promotes angiogenesis (new blood vessel formation) and helps repair these stubborn connective tissue injuries—think Achilles tendonitis, tennis elbow, or rotator cuff issues. Post-Surgical Recovery After surgery, your body needs to repair a lot of tissue quickly. TB-500 supports wound healing, reduces inflammation, and may help minimize scar tissue formation. Some protocols use it alongside traditional recovery to potentially speed up the healing timeline. Chronic Inflammation and Slow Healers Some people just heal slowly—whether due to age, diabetes, or other factors. TB-500 helps regulate the inflammatory response and promotes the cellular processes needed for tissue repair. It essentially tells your body to focus healing resources where they're needed most. Safety Profile Common Injection site redness Mild nausea Dizziness Uncommon Headache Fatigue Hot/cold sensations Serious Allergic reaction Mild fatigue or lethargy Mild headache Slight flushing Head rush or lightheadedness Temporary nausea Research Status FDA Status Research compound Safety Overview BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions. Contraindications xPregnancy xBreastfeeding xActive cancer xHistory of cancer TB-500 has shown a good safety profile across preclinical studies and limited human research. It's a fragment of thymosin beta-4, a naturally occurring protein in your body involved in healing. Most side effects are mild and transient, primarily injection site reactions. However, large-scale clinical trials are still needed to fully establish its safety profile in humans. xPregnancy or planning to become pregnant xCurrently breastfeeding xActive cancer or history of cancer xKnown allergy to peptide components xChildren and adolescents Decision Guide Choose BPC-157 if... Injury recovery Post-surgery healing Chronic pain management Gut health Choose TB-500 if... Accelerating injury recovery Tendon and ligament healing Reducing chronic inflammation Post-surgical recovery support

More references

Related material

Comparison

Quickcomparison

Dose Range BPC-157 250–500 mcg TB-500 2–5 mg Frequency Once daily Twice weekly Administration Subcutaneous injection Cycle Length 4-6 weeks Onset Speed Moderate (1-2 weeks) Eviden…

View details →
Comparison

BPC-157 vs TB-500

BPC-157 vs TB-500 A 2026 UK research comparison of BPC-157 and TB-500 — two distinct peptides with overlapping preclinical evidence in tendon, ligament and muscle repair. Mechanis…

View details →
Comparison

BPC-157 vs TB-500

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

View details →
Comparison

3. Mechanism comparison

BPC-157 mechanism (primary axes): VEGFR2 activation → angiogenesis FAK-paxillin pathway → fibroblast migration Nitric oxide system modulation EGR1 pathway engagement Protection ag…

View details →